{"name":"bluebird bio, Inc.","slug":"bluebird","ticker":"BLUE","exchange":"NASDAQ","domain":"bluebirdbio.com","description":"bluebird bio, Inc. (BLUE) is a biotechnology company focused on developing gene therapies for severe genetic diseases. The company has a strong pipeline of products, including Lenti-D for cerebral adrenoleukodystrophy and LentiGlobin for beta-thalassemia. bluebird bio has a significant market position in the gene therapy space, with several products in various stages of development. The company's products have the potential to address significant unmet medical needs and provide significant revenue opportunities.","hq":"Somerville, MA","founded":0,"employees":"","ceo":"Andrew Obenshain","sector":"Biotech — Gene Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$150M","metrics":{"revenue":90000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Lenti-D patent cliff ($1.2B at risk)","drug":"Lenti-D","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"LentiGlobin patent cliff ($1.5B at risk)","drug":"LentiGlobin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"bluebird bio Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"bluebird bio reported its fourth quarter and full year 2023 financial results, with revenue of $14.4 million and a net loss of $144.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-21","type":"deal","headline":"bluebird bio Announces Collaboration with the National Institutes of Health (NIH) to Develop Gene Therapies for Rare Genetic Diseases","summary":"bluebird bio announced a collaboration with the NIH to develop gene therapies for rare genetic diseases, with a focus on cerebral adrenoleukodystrophy and beta-thalassemia.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"regulatory","headline":"FDA Approves Lenti-D for Cerebral Adrenoleukodystrophy","summary":"The FDA approved Lenti-D for the treatment of cerebral adrenoleukodystrophy, a rare genetic disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNWFhYdzNxTzZVeDhDdnZRQ0c1VG4tY3dwa3V2QzdmMGktUFh5b2w5TWxZZ1F6eGN1anB6RzI4VVZwcm9Sc1N3clJ3SDZVems4dGVIbXVXdHhnREJUZ2EwVnVacTYyNUdnNnVBbW1kcGFhVnZWUXJyWmdvc3dMRV9xdkpLM3A?oc=5","date":"2025-09-27","type":"pipeline","source":"marketscreener.com","summary":"Genetix Biotherapeutics, Inc. Stock (BLUE) - Quote Nasdaq - marketscreener.com","headline":"Genetix Biotherapeutics, Inc. Stock (BLUE) - Quote Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZE5zQ2tId1p6VUd4Y0V6X21qdEtCOWg4UHlpN2JrcFJZaUhyZ0pRLVRVZ3J3Sm4yY01fZEtVcjRza0ZFZnhaWjNRZFVYcGU3UkJ2WTdzUU8wcW4wTUY2OXdONnNGel9QZlFSWmF3SkNrWHpyallIZC1DM1cyYm5BanFyVS0zRV9uYTJEMTlfc2VCcTZRNTZtRUc0cERSM1diUlROVHYwSjk?oc=5","date":"2025-09-18","type":"deal","source":"Fierce Pharma","summary":"After buyout, bluebird bio hatches familiar new branding as Genetix Biotherapeutics - Fierce Pharma","headline":"After buyout, bluebird bio hatches familiar new branding as Genetix Biotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQN1pGdFdITnc1OU1lTHY5dWRnMGZQeDUxOG9Jd2lKYXoxZWhaVXdPMTEyUWYwR3lHMkRjVWFwRTVSOTFUQTI4T2hvZmp2MVlWZElUempBWGtkQ05uZFRTOE5ESlBDRHZOZ2VId0UzSmRHaTRINHhUdHAtVTQ1T0Y2M1BQVWd6NzJYODl5Y1dHTWhpa3h1N2c?oc=5","date":"2025-07-02","type":"deal","source":"BioSpace","summary":"Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’ - BioSpace","headline":"Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNSlVTTF8wY0xYMks2cS1FNGkyMDZPRVBPRGpNbmN1bllRVlh2amJhbnZPMGlwNXk3Skd6OGl2SENDVEhhYkMyY0E5UUw5MUFlOXpYbTdHZEJFMndISlNRQWNHMWdiZFlodDJwa25jZF9hcmVyekZxTW9Sb05UU0xNdHVoRk0tWFdLZ2xFazRCTGVlckVOQUk0U3o2Tm1tTnNUU0pzNHJuZGhHdFgxekRFaFd3SEd1YWNKXzgwWmZDbHRMbW02RTI2ckVpYw?oc=5","date":"2025-06-02","type":"pipeline","source":"Business Wire","summary":"bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire","headline":"bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPZGU2dnFxQVdNMmFEWEVMaEJuRTdtSHBqVDcwUDF6T0tZWFp3d1lxTHM3eTJQYWQ3bXI4ZGZSSWx6T1BDOVlXUllvQlBqSTVqX0hLb2NsQVoxZm1sTlNCRkFsNUMyWUg5akgtOG0zNkFDOTlHYi1jQktRcEJ2VVY5dEhHNEV3YlpKUGVEa0hpdGVYNFBHai12c21jWWxyczNVRENwRzVWYW5rSjVCdUQtVU1TQmtEM2J0UXJxbzdPbTFlaGdXZE04WHdrTWYtazJ4UGxscTA3dmRPZw?oc=5","date":"2025-05-14","type":"pipeline","source":"Reuters","summary":"Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters","headline":"Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQcG41ODVoN3ZlMzRNWk1yMzZmOFdGMGdHZFZ0bVgydmVwZ0pPV1JMRnVFWmRGUkszQWIySTgtMExlenpRcU1YRVl3V2pHTzQxMG5UeXU4TTVwY096eXFhLWdBOS0yc2NRU2pfTEdydlh5dFFQWUF2OUlFNnFzaTVTRXgzUE5Lc0pKQ0QzQ01NLUN1UnR3dnlJOXEzUUh5VE5EZ1JzMUlFN0tldlNxQmozb1pKbV8tSGk3RHpWQ19mdzI4dzBQckNF?oc=5","date":"2025-05-13","type":"deal","source":"Fierce Pharma","summary":"Bluebird bio warns of potential bankruptcy as buyout faces another delay - Fierce Pharma","headline":"Bluebird bio warns of potential bankruptcy as buyout faces another delay","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQMnV0MWJfYld6Qkw3eE5YekJIV0JYTGV2R2M0M2wwNnpibTZQX0FNcVpBQU11RE93M3RBR1REd3JxbFFNN2ZMMnNLRWRCcjdFV2J5R2lFZUNVN2l0QkQ1dUlXSnMyalBJR0VyVGhfRDUwbllwQm8tZTcyX0xUenBfSGtLWkpPbDBpZnJfdFhjZlRwQQ?oc=5","date":"2025-04-17","type":"pipeline","source":"The Pharma Letter","summary":"bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter","headline":"bluebird bio opts to stay with Carlyle/SK takeover offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNRFI1U1J6YkhkdnlJcERiMk0tRU5kQ0ZxdUVGalhramFxYjM4SlJjUU9FbmJmN3VMbEZ0VG9VN2V0OG9xcjVVdThUalBFdmJMN3VGOW9mall1cUVLNGNQeVdCU205WlAyRjdZX3RCeDg5QW9oOURPYzFFdjl4YlVHVndiTk5RRTZMYmZGQzJhQzFaSy1zX01GeVRtWnpEbTZFNVdRa2NTMlBnTC0tT2Z3LUlfb25sVVVUcFE?oc=5","date":"2025-02-23","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering and Biotechnology News","headline":"StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOY1V5WWJjbk42Yl9BeFdpSm0tNTR5cXp4NTJob0JUOTNKOEwzVmExWVRkRWhXVnNBWFdUeFlDX0ZvVEtKNFFISnowaVVwcjhPYzcxb3BlaEtlOU9EQ29jQ2pSV0Zwb2ZhX2xnaC1rZEVEU242YmdTUWQxeExONGxndkdPQkFYTkFBa0pKbGR0dFpWVW9UUnV0UWs0b1ZRdVgyTzN4U1NB?oc=5","date":"2025-02-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"Struggling bluebird bio to go private for less than $30m - Pharmaceutical Technology","headline":"Struggling bluebird bio to go private for less than $30m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOYjZHYU5JSlpwRXRORWZuRVkzbldnZWxwOVNjSnFqN1Mta2FNVHNZbUF2Y1pVRzBfdVk1alpINDl3YlZjd0NNSEdKcjMtZnpaTjRRRUluc1BwN0V0bHNsTHY1RDJaMm1IUDFOdUozZjBDYmx1ZUQ0U2hDTTZubHdON1d3MWdfbTB5RjN5LVFB?oc=5","date":"2025-02-21","type":"deal","source":"BioPharma Dive","summary":"Bluebird, at risk of default, agrees to take-private deal - BioPharma Dive","headline":"Bluebird, at risk of default, agrees to take-private deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTTBMQm1FMnRTNWJ0b1pndldRM2lWWlRvU2VjT2l6NC1IMlJSdjEwdkxZNC1QMVE5d05CZzJRWGZ5ckhPMEc1ZE5zOHFMMDJveEZtNHprZFpYY0VMdzRoakVFVXV1VHRBQU1RSHA1bHBLWkZYSkFpWkpfQWZGelhSekpwdWNkMVY1dVNOeVd2NkQxS2c2SnNURk9KMjlCTU1SR3lTUWwwakhMMFJOeHc?oc=5","date":"2025-02-21","type":"pipeline","source":"statnews.com","summary":"Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million - statnews.com","headline":"Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNc3R6VlIyVDdyMkFHMHR6UHdBRkl6R1M0VV90NU1lRC1OT05xVTVuS1lmckhrTmxyZ19xZ0ZJemR4Y2JuelptWm1laXg4aFFQMGpzeTYwWHNRdzRnWTdiVkRJTVlVUnE3TGtmMDdkZmJHc0pjREtNT2wyU214RGIyMURQNzVfRWxOdnZ4ZW0ybjhhLXZLd0ZTcnhEX040OHlaMjh1Nm5VbGVYYVdFYnkxQmM4ZFFWUVlZSTZzeQ?oc=5","date":"2025-02-21","type":"pipeline","source":"MedCity News","summary":"Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News","headline":"Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity","sentiment":"neutral"}],"patents":[{"drugName":"Lenti-D","drugSlug":"lidube","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"LentiGlobin","drugSlug":"lidube","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Vertex Pharmaceuticals","Spark Therapeutics","Editas Medicine"],"therapeuticFocus":["Gene Therapy","Rare Genetic Diseases"],"financials":null,"yahoo":null}